Gan & Lee Pharmaceuticals. (SHA:603087)

China flag China · Delayed Price · Currency is CNY
62.06
-0.58 (-0.93%)
Mar 4, 2026, 3:00 PM CST
36.25%
Market Cap 36.94B
Revenue (ttm) 3.85B
Net Income (ttm) 925.74M
Shares Out 595.20M
EPS (ttm) 1.57
PE Ratio 39.43
Forward PE 30.27
Dividend 1.50 (2.39%)
Ex-Dividend Date n/a
Volume 5,719,832
Average Volume 5,899,052
Open 62.00
Previous Close 62.64
Day's Range 61.54 - 62.88
52-Week Range 40.40 - 82.25
Beta 0.83
RSI 33.25
Earnings Date Apr 23, 2026

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection... [Read more]

Sector Healthcare
Founded 1998
Employees 5,245
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603087
Full Company Profile

Financial Performance

In 2024, SHA:603087's revenue was 3.05 billion, an increase of 16.77% compared to the previous year's 2.61 billion. Earnings were 614.66 million, an increase of 80.75%.

Financial Statements

News

There is no news available yet.